Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
RecruitingNCT06827262
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.
Study details
- Official title
- Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
- Conditions
- Chronic Low-back Pain
- Vertebrogenic Pain Syndrome
- Interventions
- Device: Intracept™ Intraosseous Nerve Ablation
- Sponsor
- Boston Scientific Corporation
- Start date
- 2025-03-26
- Primary completion
- 2034-07
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 22
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU). * Signed a valid, IRB/EC-approved informed consent form. Exclusion Criteria: * Meets any contraindications per locally applicable Instructions for Use (IFU).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06827262